To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
Acid Ceramidase (ASAH1) Antibody
Antibody
Rabbit monoclonal antibody directed against human acid ceramidase for immunocytochemistry and immunoprecipitation applications.
MHC-I H2-Db Antibody
Antibody
Rabbit monoclonal antibody directed against mouse MHC-I H2-Db for immunoblotting and immunostaining applications.
Estimated Availability: Early 2025
MHC-I H2-Kb Antibody
Antibody
Rabbit monoclonal antibody directed against mouse MHC-I H2-Kb for immunoblotting and immunostaining applications.
Estimated Availability: Early 2025
MCU Floxed DAT-Cre Mouse*
Mouse Model
MCU Floxed DAT-Cre mice were generated by crossing floxed exons 5 and 6 of the MCU gene (Zampese et al. 2022) with mice expressing Cre recombinase under the dopaminergic-specific DAT to induce knock-out of MCU (mitochondrial Ca2+ uniporter), resulting in the loss of MCU specifically in dopaminergic cells. Model was designed by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038988
Parkin KO x Polg Mutator Mouse*
Mouse Model
Parkin KO x Polg Mutator mice were generated by crossing PolgAD257A mutant mice, lacking mitochondria polymerase proofreading function, with Parkin KO mice. Model was designed by Kelly Stauch and Howard Fox at University of Nebraska Medical Center and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:036670
iMCI-PARK Mouse*
Mouse Model
Inducible MCI-PARK (iMCI-PARK) mice, based on the ESR-NDUFS2 strain described by Fernández-Agüera, 2015, were generated by crossing mice carrying a floxed allele of mouse Ndufs2 with mice that broadly express tamoxifen-inducible cre recombinase (Tg(CAG-cre/Esr1*)5Amc that result in a conditional, body-wide knock-out of Ndufs2 following tamoxifen induction. Model was originally designed by deleting Ndufs2 only from dopaminergic neurons by D. James Surmeier at Northwestern University and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038571
GBA1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GBA1, including heterozygous and homozygous N370S and E326K mutations, among others. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP).*Heterozygous and homozygous L444P and Noncoding (rs3115534) mutations are currently in development. Estimated Availability: Q1 2026.
Ubiquitin pS65 Phosphospecific Antibody (IHC)
Antibody
Rabbit monoclonal phosphospecific antibody directed against Serine65 of ubiquitin. Suitable for immunohistochemistry applications. Detailed characterization data is published in Watzlawik et al, Autophagy 2024.
Thy-1 Wild Type Human Alpha-Synuclein Mouse (Line 61)*
Mouse Model
Transgenic mice expressing wild type human alpha-synuclein cDNA driven by the mouse Thy1 promoter. Model was developed by Eliezer Masliah and deposited by Robert Rissman at University of California San Diego, and made available through the MJFF Sponsored Tools Program. RRID:IMSR_JAX:038796
Lentiviral LRRK2 (G2019S)
Viral Vector
Lentiviral vector expressing LRRK2 mutated at residue G2019S. Lentiviral eGFP available as a control in Reporter section.
Please note: This viral vector is not intended for in vivo use.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic